Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Use of biomarkers in the discovery of novel anti-schizophrenia drugs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Rodent models of diabetic kidney disease: human translatability and preclinical validity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Animal models of pain and migraine in drug discovery

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. mTOR as a multifunctional therapeutic target in HIV infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Natural and therapy-induced antibodies to cytokines

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Schizophrenia is characterized by a diverse symptomatology that often includes positive, cognitive and negative symptoms. Current anti-schizophrenic drugs act at multiple receptors, but little is known about how each of these receptors contributes to their mechanisms of action. Screening of novel anti-schizophrenic drug candidates targeting single receptors will be based on biomarker assays that measure signalling pathways, transcriptional factors, epigenetic mechanisms and synaptic function and translate these effects to behavioural effects in animals and humans. This review discusses current states of the validity of biomarkers in the identification of novel anti-schizophrenic drug candidates.
OriginalsprogEngelsk
TidsskriftDrug Discovery Today
Vol/bind15
Udgave nummer3-4
Sider (fra-til)137-41
Antal sider5
ISSN1359-6446
DOI
StatusUdgivet - 1 feb. 2010

ID: 32199726